echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > IMS: uncover the top 5 truth of global pharmaceutical market

    IMS: uncover the top 5 truth of global pharmaceutical market

    • Last Update: 2015-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: pharmaceutical economic report 2015-06-01 according to IMS forecast, from 2013 to 2018, global brand drugs and generic drugs expenditure is expected to increase by 30%, with a compound annual growth rate of more than 5%, which will promote the annual sales of global drugs to reach a new high of $1.3 trillion by 2018 The pharmaceutical market is undergoing tremendous changes Japan and Europe are traditional pharmaceutical giants, while China, the emerging market, has become the leader of the pharmaceutical market Based on the drug sales data in 2013, by focusing on the top five markets in the global pharmaceutical industry, we can reveal the real situation of the operation of some pharmaceutical markets Us: the price of generic drugs soared in 2013: the total sales volume of drugs was 339.7 billion US dollars The Affordable Care Act issued by the US has taken measures to control the cost of health care However, due to the high drug price and large drug consumption in the US, the annual consumption of prescription drugs per capita reached 1000 US dollars, twice that of Canada, Germany and Australia The incidence rate of heart disease, COPD (chronic obstructive pulmonary disease) and diabetes in America is much higher than that in other developed countries, according to the Centers for Disease Control and Prevention Branded drugs account for the majority of healthcare budget spending in the United States, but a recent Wall Street Journal article pointed out that the price of most generic drugs in the United States has also skyrocketed It is estimated that in the past 12 months, as many as half of the small molecule generic drugs sold by drug retailers have seen their prices rise Among them, some prices have risen by 1000% and even more by 17000% Japan: high efficiency approval of new drug "Fudi" total drug sales in 2013: US $94 billion with the huge demand brought by the world population surge, Japan, the world's third largest economy, has become the world's second largest pharmaceutical market Efficient drug approval enables new drugs to enter the Japanese market quickly For example, the approval speed of opdivo of Bristol Myers Squibb in Japan is faster than that of the United States Unfortunately, due to economic stagnation and three major disasters (earthquake, tsunami and nuclear leakage) in 2011, Japan's pharmaceutical market declined significantly However, the good news is that Japan has made some achievements in a large number of drug R & D innovations In the past, Japanese pharmaceutical companies used to do research and development "behind closed doors", but in recent years, it has changed Takeda pharmaceutical, Japan's largest pharmaceutical company, is speeding up its pace of integration with the world, and has announced the appointment of Christopher Weber, former CEO of GlaxoSmithKline, as its chief executive This set a precedent for Takeda to hire foreigners as its chief executive officer, and the appointment of foreigners as its head also showed that Takeda pharmaceutical began to look at the international market China: the diabetes market meets the great opportunity In 2013, the total drug sales volume is 86.8 billion US dollars China's population accounts for 20% of the world's total population If China continues to achieve the goal of full coverage of 1.35 billion people's health insurance, by 2020, the next five-year plan will be completed, and China's drug market share will account for 34% of the global pharmaceutical market In fact, many people believe that China is destined to become the world's largest pharmaceutical market However, with the expected excitement, developing the Chinese market for all pharmaceutical companies is much more complicated than expected It has always been the focus of development to rush to imitate the approved new drugs in the United States and speed up their listing, but China's regulatory environment is complex, regional differences are large, and intellectual property protection needs to be strengthened The current economic recession has also increased the pressure of market development According to the data analysis of Bloomberg, Pfizer, MSD, GSK and other eight pharmaceutical manufacturers in the Chinese market achieved 40% rapid growth in 2011, but the growth slowed down to 20% in 2013 China is still a market with bright spots Large pharmaceutical companies can invest billions of dollars to seek strategic alliances Pfizer, which has pharmaceutical manufacturers in Dalian, Suzhou and Wuxi, has launched more than 40 innovative drugs into the Chinese market At the same time, Pfizer also holds shares in Shanghai pharmaceutical, China's largest pharmaceutical distributor, and is also a partner of Zhejiang Haizheng pharmaceutical industry in the development of generic drugs China's diabetes market is facing a huge development opportunity According to IMS data, China's diabetes market is expected to grow by 20% to US $3.2 billion by 2016 Johnson & Johnson also hopes that its first diabetes drug, invokana, will be successfully developed in China Sales of monsadon's blockbuster januvia have fallen due to fierce competition in the US diabetes market, but there is hope to open a new market in China Other US pharmaceutical giants, such as abbvie, Abbott, Amgen and Eli Lilly, mostly have investments in China, and many also have joint ventures and manufacturing plants Germany: high entry threshold "scare back" drug companies total drug sales in 2013: 45.8 billion US dollars Germany is the leader of European pharmaceutical market, but its growth rate is slow According to global data, a global research and consulting firm, the German drug market is expected to grow by 1.7% from 2015 to 2020 Since 2011, Germany is no longer a "free medical market", and its medical product market reform act (amnog) has come into force Amnog reform measures require pharmaceutical companies to prove the added value of innovative drugs, otherwise they will face a very low reimbursement rate Amnog has rejected some innovative drugs For example, idelalisib (orphan drug for the treatment of chronic lymphocytic leukemia), a blockbuster new drug of Gilead Sciences, has been approved by the U.S FDA, but relevant German institutions insist that the clinical value of idelalisib is not sufficient Therefore, faced with the double pressure of not only proving the effectiveness of new drugs, but also proving that new drugs improve the level of treatment standards, some pharmaceutical companies have to choose to automatically give up the supply of new drugs to Germany France: the growth is stagnant In 2013, the total drug sales volume is 37.2 billion US dollars France has always been a big market for brand drugs In fact, 90% of French doctors prescribe drugs, which is more likely than other countries However, due to the restrictions of retail medicine profits and medicine price management, the French medicine market has stagnated IMS analysis shows that from 2012 to 2013, the French pharmaceutical market grew by only 1%, compared with 4% in the previous year However, even if the growth rate is only 1%, France is one of the few countries in Europe where the pharmaceutical market continues to grow The overall growth rate of EU pharmaceutical market is - 1%, showing a declining trend For large pharmaceutical companies, the shrinking EU market is a serious problem Because the EU is a relatively easy market to promote and enter, innovative drugs for large pharmaceutical enterprises, especially expensive biological drugs, are often favored by consumers with economic strength For example, in the past few decades, the cost of targeted cancer drugs in the European Union has increased rapidly, accounting for up to 40% In contrast, the emerging pharmaceutical market, such as China, gives priority to low-cost drugs in public health care.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.